Characterization of a Novel AAV-hTau Mouse Model of Tauopathies with Parkinsonian Features
AAV Tauopathy (AAV-Tau) Model Overview
For this model of Progressive Supranuclear Palsy and Corticobasal Degeneration, we perform unilateral stereotaxic inoculation of AAVs overexpressing wild-type human tau (MAPT) into the substantia nigra of C57BL/6 mice at ~2-3 months-of-age. This mouse model reproduces several key features of human tauopathies, including:
- Reduction of dopaminergic neurons in the substantia nigra pars compacta
- Dopaminergic denervation of the ipsilateral striatum
- Aggregates of phosphorylated tau in cell bodies and neurites
- Activated microglia
- Reactive astrocytes
- Motor dysfunction
- Brain atrophy (substantia nigra, midbrain, caudate-putamen) measured by in vivo MRI scans
AAV-Tau Model Generation
A general schema for the model generation is:

For this specific model, we use C57BL/6 mice at ~8-12 weeks-of-age. We then perform stereotaxic injection of AAV vectors into the vicinity of the substantia nigra. We use digital stereotaxic devices with automated microinjectors for high accuracy & precision.
Studies using this model can be rapidly initiated. The in vivo phase of the study typically lasts approximately 6 weeks. As such, generation of readouts can be provided in a relatively short time frame, especially compared to conventional tau transgenic models of Alzheimer's disease & tauopathies.
Our Validated Measures
- Hindlimb clasping test
- Tail suspension swing test
- Cylinder test
- Rotarod test
- MRI brain atrophy
- IHC & multiplex immunofluorescence
Learn more about the translatability of this model to human tauopathies.
Model Characterization
The Interactive Presentation below allows you to explore our characterization of our AAV-Tau mouse model, including in vivo data and high-resolution images of entire Multiplex Immunofluorescence tissue sections.
You can simply navigate through this "Image Story" using the left panel.
You can pan around the high-resolution microscopy images using the left mouse button. You can zoom in and out using the mouse/trackpad (up/down) or the + and - buttons in the upper left corner. You can toggle (on/off), change color, and adjust image settings for the channels and segmentations in the Control Panel in the upper right corner.
We suggest using Full Screen Mode for the best interactive experience.
Learn more about our characterization of our AAV-Tau mouse models, our validated measures, and our Preclinical Neuroscience CRO services.
Discover more of our Alzheimer's Disease & Tauopathies Models
Related Content
Up-to-date information on Alzheimer's Disease & Tauopathies and best practices related to the use of translational biomarkers for the evaluation of therapeutic agents in animal models.
Tau-related Atrophy is Independent of β-Amyloid & APOE ε4
Using MRI, Tau PET, and Amyloid PET imaging biomarkers from the ADNI study, we show that Tau is more strongly linked to brain atrophy than β-amyloid or APOE ε4.
MRI Measures of Disease Progression for PSP Clinical Trials
MRI biomarkers (including brain atrophy) from the 4RTNI and FTLDNI natural history studies of Progressive Supranuclear Palsy (PSP).
MRI & Corticobasal Degeneration (CBD)
Longitudinal MRI brain atrophy measures from the 4RTNI and FTLDNI studies including sample size calculations for clinical trials of Corticobasal Degeneration.
Decreased Brain Glucose Metabolism in MCI is Driven by Tau
We demonstrate a more significant role of tau than β-amyloid in the reduction of cerebral glucose metabolism by analysis of PET images from the ADNI study.
Astrocyte Morphology in Alzheimer's Disease
An overview of astrocyte morphological analysis and the applications to neurodegenerative disease research and drug discovery & development.
Astrocytes & Amyloid-β Mouse Models of Alzheimer's Disease
Analysis of astrocyte morphology in the amyloid-β plaque microenvironment provides a sensitive measure of disease progression in transgenic mice.
Amyloid-β & Inflammatory Microenvironment in Alzheimer's Mice
We have analyzed the complex spatial relationships between β-amyloid plaques, activated & resting microglia, and astrocytes in an APP/PS1 transgenic model.
[18F]DOPA PET in Parkinson’s Disease Clinical Trials
How [18F]DOPA PET is used to monitor disease progression & response to therapeutic intervention in Parkinson’s disease & movement disorders clinical trials.